The same things were said when they hired the guy from Merck.
Oh, I was supposed to pick one? Deny, of course. The line comes from Shakespeare, specifically Hamlet, act III, scene 4, lines 206 and 207: "For 'tis sport to have the engineer/ Hoist with his own petar …"
The Melancholy Dane is chuckling over the fate he has in store for his childhood comrades, Rosencrantz and Guildenstern, who are plotting to have him killed. Deferring his existential crisis for a moment, Hamlet turns the plot on the plotters, substituting their names for his in the death warrant they carry from King Claudius.
He continues: "But I will delve one yard below their mines/ And blow them at the moon." The key word is "mines," as in "land mines," for that's what a petard is (or "petar," as Shakespeare puts it — people couldn't spell any better then than now). A small explosive device designed to blow open barricaded doors and gates, the petard was a favorite weapon in Elizabethan times.
Hamlet was saying, figuratively, that he would bury his bomb beneath Rosencrantz and Guildenstern's and "hoist" them, i.e., "blow them at the moon." Dirty Harry couldn't have put it any better.
The word "petard," we note with a grin, comes from the Middle French peter, which derives in turn from the Latin peditum — the sense of which is "to break wind." Which must mean either that the French had a serious gas problem in those days, or that the petard was of something less than nuclear impact.
— Cecil Adams
Seems like institutions are holding firm, I would take a look at some actual data and facts. I have never seen a company that gets more funding for trials from outside sources.
Equity Ownership ADXS
Market Cap (Mil USD) 296
# of Institution Owners 123
# of Fund Owners 138
% Owned by Institutions 60.81
% Owned by Funds 23.12
% Owned by Insiders 4.02
Oh course JUNO is only down 26% so far, ADXS down from 30 bucks to 5 with a hold that has since been lifted and otherwise all good news.
The thing that has always impressed me about ADXS is the support their trials get from outside sources.
I'd like to see some proof of your statement. I see as reported today on Morningstar that there remains 126 institutional owners, unchanged.
Oh wait, you don't have any.
You guys crack me up! Thanks for the "insight".
But not enough money to be able to keep from bashing for 10 cents a post though.
"Twenty-seven percent of patients in the JCAR15 trial experienced a severe inflammatory response to the altered cells, and 15 percent had serious nervous system side effects."
This is not a minor issue and there are some following the therapy who say this could be a deal breaker, at least in some circumstances.